Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent Erlotinib with Chemotherapy in SCCHN
NCT00448240Phase 3Terminated
- Sponsor
- Henry Ford Health
- Start
- Feb 2007
- Primary completion
- Jan 2012
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of erlotinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Henry Ford Health. Primary endpoint: Tumor Response Rate at 18 weeks. Started Feb 2007; status: terminated.
02
Drugs
erlotinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00448240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00448240.